Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 204,321 shares of the company’s stock after selling 3,165 shares during the period. Amalgamated Bank’s holdings in Roivant Sciences were worth $2,417,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ROIV. TOMS Capital Investment Management LP purchased a new stake in Roivant Sciences during the 3rd quarter worth approximately $46,333,000. FMR LLC boosted its holdings in Roivant Sciences by 5.6% in the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after purchasing an additional 2,593,910 shares during the period. Geode Capital Management LLC grew its stake in Roivant Sciences by 23.2% during the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after purchasing an additional 1,460,205 shares in the last quarter. State Street Corp increased its holdings in Roivant Sciences by 6.1% during the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after purchasing an additional 1,118,561 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Roivant Sciences by 49.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company’s stock valued at $26,625,000 after purchasing an additional 762,953 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Activity at Roivant Sciences

In other news, COO Eric Venker sold 218,041 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the completion of the sale, the chief operating officer now owns 896,869 shares in the company, valued at $9,345,374.98. This represents a 19.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the company’s stock in a transaction on Monday, January 13th. The stock was purchased at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 2,388,170 shares of company stock worth $27,612,299 in the last 90 days. 7.90% of the stock is owned by insiders.

Roivant Sciences Price Performance

Shares of ROIV opened at $10.74 on Friday. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06. The stock has a market cap of $7.66 billion, a PE ratio of -71.60 and a beta of 1.25. The firm has a fifty day moving average price of $11.08 and a 200 day moving average price of $11.58.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, equities analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

ROIV has been the topic of a number of recent research reports. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences has a consensus rating of “Buy” and an average price target of $18.08.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.